<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03899324</url>
  </required_header>
  <id_info>
    <org_study_id>CUREPARK/OP105018.BAT</org_study_id>
    <nct_id>NCT03899324</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of Bumetanide in Parkinson's Disease</brief_title>
  <acronym>CUREPARK</acronym>
  <official_title>A Randomized Double-blind Placebo-controlled Multicenter Proof-of-concept Trial to Assess the Efficacy and Safety of Bumetanide in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B&amp;A Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B&amp;A Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is multicentre, proof of concept, randomized, double-blind, parallel-group,
      placebo-control study in 40 Parkinson's Disease (PD) patients. Patients will be randomized in
      2 groups receiving Bumetanide or placebo for 4 months:

        -  Group 1 (20 PD patients): bumetanide

        -  Group 2 (20 PD patients): placebo intake identically to group 1.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2019</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint of this study is the change from baseline (V2) to endpoint (V5) in the MDS-UPDRS III motor score, evaluated 1 hour after the intake of the study treatment (Bumetanide or placebo) in patients in the OFF state.</measure>
    <time_frame>Between Day 1 and Day 120</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from V2 to V5 of the MDS-UPDRS part III and part I measured in a patient in the ON state.</measure>
    <time_frame>Between Day 1 and Day 120</time_frame>
    <description>Movement Disorder Society Unified Parkinson's Disease Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of scores of the MDS-UPDRS part II, III and IV during the trial, at D1 (V2), D30 (V3), D60 (V4) and D120 (V5).</measure>
    <time_frame>Day 1, Day 30, Day 60, Day 120</time_frame>
    <description>Movement Disorder Society Unified Parkinson's Disease Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stand-Walk-Sit test at D1 (V2), D30 (V3), D60 (V4) and D120 (V5).</measure>
    <time_frame>Day 1, Day 30, Day 60, Day 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events collected at each visit and phone calls.</measure>
    <time_frame>Throughout the completion of the study, from Day 1 to Day 135</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Unified dyskinesia rating scale at D1 (V2), D30 (V3), D60 (V4) and D120 (V5).</measure>
    <time_frame>Day 1, Day 30, Day 60, Day 120</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Awaken time spent in the OFF state, in the ON state with and without dyskinesia.</measure>
    <time_frame>Between Day 0 (Screening) and Day 1 (V2), then between Day 60 (V4) and Day 120 (V5)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient's Clinical Global Impression (CGI) score at D1 (V2), D30 (V3), D60 (V4) and D120 (V5).</measure>
    <time_frame>Day 1, Day 30, Day 60, Day 120</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Group 1: Experimental Bumetanide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bumetanide with a titration period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Placebo comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo intake identically to group 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bumetanide white, oblong, scored tablet</intervention_name>
    <description>Bumetanide with a titration period</description>
    <arm_group_label>Group 1: Experimental Bumetanide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo white, oblong, scored tablet</intervention_name>
    <description>placebo intake identically to group 1</description>
    <arm_group_label>Group 2: Placebo comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Idiopathic Parkinson's disease fulfilling the UK Parkinson's Disease Brain Bank
             (UKPDSBB) criteria (cf. Appendix VII)

          2. 40 &lt; Age &lt; 80 years old

          3. Hoehn &amp; Yahr 1.5-4 (OFF stage)

          4. Walking and balance or freezing ≥ 1in the MDS-UPDRS II

          5. Motor fluctuation defined by a score ≥ 1 on the item &quot;time spent in the OFF state&quot; of
             the MDS-UPDRS IV

          6. Dose of L-DOPA ≥ 150 mg/d (concomitant treatment)

          7. PD medications regimen stable for at least 3 months

          8. Patients expected to remain on stable doses of PD medications during all the study

          9. Covered by Health Insurance System

         10. Able to understand and to sign the informed consent prior to selection

         11. Negative pregnancy test at screening

         12. Blood Pressure (BP) and Heart Rate (HR) considered Non Clinicaly Significant (NCS) by
             investigators

         13. Electrocardiogram (ECG) recording on a 12-lead ECG considered NCS by investigators

         14. Laboratory parameters within the normal range of the laboratory. Individual values out
             of the normal range can be accepted if judged clinically non relevant by the
             Investigator

        Exclusion Criteria:

          1. Atypical parkinsonism or drug-induced parkinsonism

          2. Cognitive impairment (MMSE ≤ 24)

          3. Active psychiatric disorder (mood disorders, hallucinations or delirium with strong
             functional impact and not controlled by medication or which happened during the last 3
             months before inclusion)

          4. Treatment by Deep Brain Stimulation or continuous infusion of apomorphin/dopa gel

          5. Renal or hepatic insufficiency

          6. Electrolyte disturbances

          7. A corrected QT (QTcF) interval &gt;450ms for male or &gt;470ms for female on the
             electrocardiogram

          8. Any medical condition that might interfere with the protocol except those defined in
             Section 5.3

          9. Contraindications to bumetanide : persistent anuria, hepatic encephalopathy included
             coma

         10. Women pregnant, nursing or of childbearing age without effective contraception.
             Patients should not be enrolled if they plan to become pregnant during the time of
             study participation

         11. Patient unable to attend scheduled visits or to comply to the protocol

         12. Patient under legal guardianship or judicial protection

         13. Patient in the exclusion period of another protocol

         14. No possibility of contact in case of emergency

         15. Known allergic reactions induced by Burinex (Bumetanide)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Denis Ravel, PhD</last_name>
    <phone>04 38 37 27 40</phone>
    <email>denis.ravel@initial-rd.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fanny Kayser</last_name>
    <phone>04 38 37 27 40</phone>
    <email>OP1050@eurofins.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LE DILY Séverine</last_name>
      <phone>02 40 16 52 86</phone>
    </contact>
    <investigator>
      <last_name>Philippe DAMIER, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Damier P, Hammond C, Ben-Ari Y. Bumetanide to Treat Parkinson Disease: A Report of 4 Cases. Clin Neuropharmacol. 2016 Jan-Feb;39(1):57-9. doi: 10.1097/WNF.0000000000000114.</citation>
    <PMID>26757306</PMID>
  </reference>
  <reference>
    <citation>Lozovaya N, Eftekhari S, Cloarec R, Gouty-Colomer LA, Dufour A, Riffault B, Billon-Grand M, Pons-Bennaceur A, Oumar N, Burnashev N, Ben-Ari Y, Hammond C. GABAergic inhibition in dual-transmission cholinergic and GABAergic striatal interneurons is abolished in Parkinson disease. Nat Commun. 2018 Apr 12;9(1):1422. doi: 10.1038/s41467-018-03802-y.</citation>
    <PMID>29651049</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 29, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2019</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bumetanide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

